(Incorporated in Belgium)

We are a Phase 2 clinical biotech focused on discovering and/or developing new treatments for diseases in the immunology and inflammatory category.

Our leading product candidates are:

*Ontunisertib (AGMB-129) – An oral treatment for Crohn’s Disease with fibrostenosis, and

*AGMB-447 –  An inhaled treatment for idiopathic pulmonary fibrosis (IPF).

Our product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. Our initial focus for the treatment of fibrosis is through inhibition of one of the key signaling pathways involved in fibrosis, the transforming growth factor β, or TGFβ, pathway. Our mission is to develop disease-modifying therapeutics that aim to resolve fibrosis and restore organ function to enable patients with these disorders to live fuller and healthier lives.

Note: AgomAb Therapeutics has not produced any product revenue to date.

Note: AgomAb Therapeutics has incurred net losses in each year since its inception in April 2017, including total comprehensive losses of €46.4 million and €11.4 million for the years ended December 31, 2024, and December 31, 2023, respectively.

Note: As of September 30, 2025, AgomAb Therapeutics had an accumulated net loss of €164.3 million. 

Note: Net loss shown in the chart is in U.S. dollars (converted from euros) for the 12 months that ended Sept. 30, 2025.

(Note: AgomAb Therapeutics filed its F-1 for its IPO on Jan.16, 2026, without disclosing the terms. Estimated proceeds are $100 million, a placeholder figure.)